US Stem Cells Research Industry

• Publication date: February 2011

This report analyzes the US Market for Stem Cells Research in US$ Million. Annual forecasts are provided for the period 2006 through 2015. The report profiles 92 companies including many key and niche players such as Advanced Cell Technology, Inc., Athersys, Inc., BioE, Inc., Cryo-Cell International, Inc., Cytori Therapeutics, Inc., Edstrom Biosciences, Inc., Geron Corporation, International Stem Cell Corporation, Neuralstem, Inc., NeuroGenera...

This report analyzes the US Market for Stem Cells Research in US$ Million. Annual forecasts are provided for the period 2006 through 2015. The report profiles 92 companies including many key and niche players such as Advanced Cell Technology, Inc., Athersys, Inc., BioE, Inc., Cryo-Cell International, Inc., Cytori Therapeutics, Inc., Edstrom Biosciences, Inc., Geron Corporation, International Stem Cell Corporation, Neuralstem, Inc., NeuroGeneration, Inc., Osiris Therapeutics, StemCells, Inc., ThermoGenesis Corp., and ViaCord, LLC. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Biological Therapy Industry in the United States

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONs 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
Types of Stem Cells 3
Embryonic Stem Cells 3
Adult Stem Cells 3

2. MARKET OVERVIEW 4
Overview 4
Major Achievements Thus Far 4
Stem Cell Therapy Gaining Acceptance 4
New Growth Areas 5
Orthopedic Products - A potential growth sector 5
Utilitarian Functions of Cord Blood Stem Cells 5
Umbilical Cord Stem Cells in the Treatment of Hepatic Diseases 5
Human Umbilical Cord Blood-Derived Stem Cells to Synthesize
Insulin 5
Challenges 5
Stem Cell Research And the Ethical Angle 6

3. MARKET DYNAMICS AND TRENDS 7
North America Dominates Global Stem Cells Market 7
Stem Cells Breakthrough Reshaping the Area of Medicine 7
New Technologies Draw Significant Attention 7
Ethical Issues and Nascent Stage - Key Market Restraints for
Stem Cells 8
Medical Tourism Picks Up in Stem Cell Therapy 8
Government Regulations Fail to Prevent Medical Tourism in
Stem Cell Therapy 9
US and Japan Surge Ahead of Europe in Stem Cell Patents 9
Table 1: Global Stem Cells Patent Analysis By Market (2008):
Percentage Breakdown of Number of Patents Issued for US,
Japan and Europe (includes corresponding Graph/Chart) 10

Table 2: Global Stem Cells Patent Analysis By Product (2008):
Percentage Breakdown of Number of Patents Issued for Adult
Stem Cells, Human Embryonic Stem Cells, Mesenchymal Stem
Cells, Hematopoietic Stem Cells, Neuronal Stem Cells and
Others (includes corresponding Graph/Chart) 10

Table 3: Leading Stem Cell Companies by Patents (2008):
Percentage Breakdown of Number of Patents Secured for Geron
Corp., Osiris Therapeutics, Olympus Corporation, Wisconsin
Alumni Research Foundation, Kourion Therapeutics AG, Japan
Science & Tech Agency and Others (includes corresponding
Graph/Chart) 10

4. STEM CELLS MARKET DYNAMICS - BY TYPE 11
Adult Stem Cells Hold Tremendous Potential 11
A Low Risk Investment 11
Adult Stem Cells Garner More Investments for Research 12
Low Versatility - A Major Limiting Factor for Adult Stem Cells 12
Hematopoietic Stem Cells - Enjoying Enduring Success 12
The Restraining Factors 12
Mesenchymal Stem Cells - A Promising Therapeutic Option 13
Difficulty in Isolation and Lower Understanding Hampers Growth 13
Induced Pluripotent Stem Cells - An Alternative to ESCs 13
A Peek Into the Discovery of iPS 13
Drug Development - A Major Application for iPS 14
Regenerative Medicine 14
Establishing iPS Cell Banks 15
Intractable and Congenital Disease Treatments 15
Repairing Organs 15
Embryonic Stem Cells to Transfigure the Field of Medicine 15
Lack of Safety and Efficacy Data Remains A Concern 16

5. STEM CELLS RESEARCH BY APPLICATION 17
Stem Cells in Disease Management 17
Stem Cell Therapy in Regenerative Medicine 17
Stem Cell Therapy - A Promising Treatment for Neurological
Disorders 18
Large-Scale Studies Imperative to Substantiate Early Positive
Results In Cardiovascular Diseases 18
Stem Cell Therapy in Cancer 18
Stem Cells Set Foot in Personal Care 19
Aging Population to Drive Orthopedic Stem Cell Market 19
Other Diseases 20
Stem Cells in Drug Discovery 20
Tools for Drug Development 21

6. REGULATORY ENVIRONMENT 22
Laws Governing Stem Cells Research - The Divided World 22
Laws and Regulations in Stem Cells Research in Select Countries 22

7. PRODUCT OVERVIEW 23
Stem Cell Research 23
Stem Cells - Description 23
Types of Stem Cells 23
Embryonic Stem Cells 23
mES and hES 23
R-NSCs 24
Adult Stem Cells 24
Hematopoietic Stem Cells 25
Mesenchymal Stem Cells 25
Umbilical Cord Stem Cells 25
Neuronal Stem Cells 25
Dental Stem Cells 25
Pluripotent Adult Stem Cells 26
Other Key Cell Types 26
The Stem Cell Line - Cell Division 26
Stem Cells - Properties 27
Ability to Renew on its Own 27
Potency 27
Definitions of Various Potencies 27
Identification of Stem Cells 27
Stem Cells - Applications 28
History of Stem Cells 28
Stem Cells - Services and Products 29
Significance of Stem Cell Products/Services 29

8. RESEARCH BREAKTHROUGHS 30
Parthenogenetic Stem Cells Holds Potential in the Treatment of
Thalassemia 30
hESCs - A Potential Source for Unlimited Supply of Functional
Platelets 30
Sperm-Producing Stem Cells For Diabetes Treatment -
Researchers Explore Prospects 31
Cellonis Achieves Outstanding Results of Its Stem Cell Therapy
for Diabetes 31
Stem Cells From Fallopian Tubes - A Prospective New Source 31
Stem Cells from Fat - Enhancing Stem Cells Accessibility 32
Skin Cells to Stem Cells - A New Promising Method 32
Stem Cells to Repair Brain Damage After A Stroke 33
ACT Shows hESCs’ Potential to Become An Unlimited Source for
Functional RBCs 33

9. PRODUCT INNOVATIONS/INTRODUCTIONS 35
StemCells Launches New Antibody Reagents 35
Arteriocyte Introduces Nanex Hematopoietic Stem Cell Expansion
Kit 35
Vitrolife Unveils Growth Factors and Cytokines for Stem Cell
Cultivation 36
BioTime to Introduce New Product Line of Stem Cell Products 36
Chemaphor Introduces Stem Cell Regenerative Therapy 36
Stempeutics Research Malaysia to Launch Ischemic CS Therapy 36
Vitro Diagnostics Launches Novel Serum-free Stem Cell Growth
Medium 36
ThermoGenesis to Launch Res-Q System 37
Invitrogen to Introduce New Technology for Safe Stem Cell
Treatment 37
Millipore Unveils MilliTrace™ Stem Cell Lines 38
Millipore Unveils ESGRO Complete™ PLUS medium 38
Bayer Launches Reformulated Liquid Leukine® 38
Shenzhen Beike Biotechnology and CMC Launch NBPD's SCRM
Industrial Project 38
Vitro Unveils New Products Supporting Stem Cell Research 39
Endogenous Stem Cells Activators Introduces KRONOS IV 39
ArunA Biomedical and Open Biosystems Launch iPS Kit 40
Invitrogen Introduces Neon Transfection Device 40
Invitrogen Introduces Xenogeneic-Free Media 40
NanoInk Unveils NanoStem Cell Division 40
Advanced Cell Technology Unveils New Process for Functional
Hepatocytes Generation 41

10. RECENT INDUSTRY ACTIVITY 42
NeoStem Merges with Progenitor Cell Therapy 42
EHS Enters into Joint Venture with Celulas Genetica 42
RJ to Form New Subsidiary 42
NuPotential and VistaGen Receive NIH Grant for Development of
iPS Cells (US) 42
BioCells Argentina Launches Dental Pulp Stem Cells Storage
Program 43
EHSI Forges Option Deal with OceanBASIS 43
EHSI and Regenetech Ink License Agreement 44
Transposagen Biopharmaceuticals and CDI Ink Non-exclusive
License Agreement 44
Kiadis Signs Licensing Agreement with Hospira to Develop and
Market Hematology Product 44
ACT Obtains FDA Approval for Human Clinical Trials of hESCs
for Dry AMD 44
OncoMed Commences Phase I Clinical Trial of OMP-59R5 45
Advanced Cell Technology and Roslin Cells Ink MoU 45
Mesoblast Takes Over Angioblast 46
Power3 Medical Products and Rozetta-Cell Life Sciences to Merge 46
University of California and BioTime Ink Material Transfer
Agreement 46
ISCO And John Mauldin Commence Marketing Alliance for Skincare
Products 47
Cord Blood America Inks Letter of Intent to Take Over Cryo-
Cell Mexico 47
Mesoblast Enters into Stem Cell Marketing Deal with US Company 47
Bayer HealthCare Enters into Alliance with OncoMed
Pharmaceuticals 47
SiriCell Technologies Acquires Remaining Stake in
International Stem Cell JV 48
StemCells Receives Swissmedic Approval for Neural Stem Cells
Trial In Chronic Spinal Cord Injury 48
ACT Obtains FDA Clearance for Human Clinical Trials of hESCs
for SMD 48
ReNeuron Treats First Patient in Stem Cell Therapy Clinical
Trial for Stroke 49
Amedica/US Spine Inks a Licensing and Distribution Agreement
with BioDlogics 49
Vet-Stem Inks Sub-Licence Agreement with Australian Veterinary
Stem Cells 50
Athersys Obtains FDA Approval for Phase II Trial for IBD Using
MultiStem® 50
Stemedica and AnC Form Stem Cells JV 50
Fate Therapeutics Enters into Collaboration and Licensing
Agreement with BD 50
BrainStorm Obtains Clearance for Stem Cell Therapy Clinical
Trial for ALS in Israel 51
Shrink Nanotechnologies Enters Final Stage of StemDisc
Commercialization 51
Cryo-Cell’s License Partner S-Evans Biosciences Opens New
Laboratory 51
Geron Receives FDA Approval to Initiate Clinical Trials of
hESCs for Treating Acute Spinal Cord Injuries 51
Cytori Therapeutics' Celution System Obtains European Approval 52
TGA Grants Approval to Mesoblast to Supply MPC Products 52
BioTime Inks Partnership with Hadasit Bio to Take over ES Cell
International 52
AssureImmune and Banco Merge 53
Salk Institute to Use Cyntellect’s Cell Processing Workstation
LEAP™ 53
STEMCELL Inks Agreement with Stanford University for Virus
Free Technique 53
NeoStem Inks Partnership Agreement with Catholic Church 53
Stemgent Signs Deal with Miltenyi to Co-develop and Market
Stem Cell Research Products 53
BioTime Acquires ES Cell International 54
Cipla Enters into Partnership with Stempeutics to Enter Stem
Cell Segment 54
Vitro Diagnostics Signs Contract with HemoGenix 54
Fate Acquires Verio Therapeutics 55
Vitrolife Inks Licensing Agreement with Finn-Medi Research 55
AXM Pharma to Establish Stem Cell Plant 55
Stem Cell Therapy Merges with Histostem 55
Cord Blood America Enters into Contract with BioE for Cord
Blood Processing System 55
Pfizer Acquires Rights to Athersys’ Stem Cell Therapy 56
Enterprise Investors Acquires Large Interest in PBKM 56
Fate Therapeutics to Distribute Stem Cell Products through
Becton Dickinson 56
NHMC Merges with BioStem Genetics 57
Riverside Acquires Crioestaminal 57
Cryo-Cell International Signs Distribution Agreement with S-
Evans Biosciences 57
Jordanian Stem Cell Purchases Stemedica International’s Stem
Cell Technology 57
BrainStorm Enters into Agreement with Protein Production Services 58
Novartis Acquires Opexa’s Stem Cell Technology 58
ThermoGenesis Expands Alliance with Celling Technologies 58
Bioheart to Test MyoCell SDF-1 in REGEN Trial 59
Osiris Initiates Enrolment for Prochymal Phase II Clinical
Trial for Type I Diabetes Treatment 59
Stirling Divests Interest in Australian Stem Cell Healthcare 60
iZumi Bio Merges with Pierian 60
iZumi Collaborates with CiRA to Expand iPSC Technology 60
Novartis Forges Research and Development Partnership Agreement
with Epistem 61
Healthcare of Today Acquires Regenetech 61
Neuralstem and China Medical University to Co-develop
Treatment for Stem Cell Stroke 62
Cytori Inks Agreement with GE Healthcare for StemSource®
Technology Commercialization 62
MedCell Bioscience Merges with NovaThera 63
StemCells Acquires Stem Cell Sciences 63
BioSante Pharmaceuticals Merges with Cell Genesys 63
Cell Therapeutics Enters into Joint Venture with Spectrum
Pharmaceuticals 64
Cryo-Cell International Enters into Collaboration with
Cryopraxis Cryobiology 64
Embryome Sciences Signs Partnership Agreement with
Reproductive Genetics Institute 65
ENKAM Inks Licensing Agreement with STEMCELL 65
Sigma-Aldrich Inks Distribution Agreement with AlphaGenix 66
ThermoGenesis and Celling Technologies Extend Collaboration 66
Vivalis Enters into Collaboration with SAFC Biosciences 66
ReNeuron Enters into Agreement with Angel Biotechnology Holdings 67
Cellartis Signs Agreement with ReproCELL 67
Cellartis and AstraZeneca Extend Collaboration 68
Embryome Sciences and Millipore Sign Co-Marketing Agreement 68
Cytori Enters into Partnership with GE Healthcare 68
Stemgent Enters into Co-Exclusive Marketing Agreement with
CellDesign 69
MultiCell Technologies and Maxim Biotech Sign R&D Agreement 70
GE Healthcare Collaborates with Geron Corporation 70
Moraga Biotechnology Licenses BLSCs to Pharmacells 71
CordLife Develops Stem Cell Therapies in India 71
NsGene Receives European Patent Rights 72
Pfizer to Invest in Stem Cell Research 72
SCTI Commences Histostem Products Distribution Process 72
Geron Secures FDA Approval for Human Trial of Embryonic Stem
Cell-Based Therapy 73
BioE Obtains FDA Marketing Approval for PrepaCyte-CB 73
StemCells Obtains FDA Approval for Phase I Clinical Trial of
HuCNS-SC® Cells in Treatment of PMD 73
Athersys Obtains IND for Using Multistem in Treating Ischemic
Stroke 74
Athersys Presents Initial Dosing Data of MultiStem® Phase I
Trial in AMI 74
ACT Creates Five Lines of hESCs Without Embryo Destruction 74
BioE Inks Agreement with StemSoft 75
ACT’s Technology Generates 140 Cell Types from hESC 75
ACT Develops Process for Generating Functional Hepatocytes
from hESCs 76
Applied Biosystems Merges with Invitrogen 76
Bennett, Coleman and Co Acquires Stake in Stem One Biologicals 76
BMXP Holdings Acquires Freedom Environmental Services 76
Saints Capital Completes Neuronyx Acquisition 77
Intercity Acquires Exordia 77
iPS and Stem Cell Merge with CDI Merge 77
Biohellenika Acquires Exclusive Rights of Cytori's StemSource
Cell Bank 78
International Stem Cell Signs Agreement with Millipore
Corporation 78
ReNeuron Enters into Agreement with Angel Biotechnology 78
ThermoGenesis and Celling Technologies Ink a Distribution
Agreement 79
BioTime and Embryome Ink a Deal with International Stem Cell 79
Cryo-Cell Enters into Agreement with Saneron 80
Genzyme Enters into Alliance with Osiris 80
VivoMedica Enters into Collaboration with Cellartis 81
Histostem Signs MOU with Stem Cell Therapy 81
Vantus Inks Agreement with US Davis Center for Equine Health 81
Stem Cell Sciences Enters into Agreement with Pfizer 82
Sigma-Aldrich Inks Distribution Agreement with AlphaGenix 82
Cellartis Signs Agreement with Pfizer 83
Ortec Changes Corporate Name to Forticell Bioscience 83
FDA Grants Approval to Genzyme's Mozobil 83
Pfizer Inaugurates Pfizer Regenerative Medicine Research Facility 84
Stem Cell Therapeutics Receives Australian Patent 84
STEMCELL Technologies Secures License Rights to Geron IP 84
BioTime Starts Embryonic Stem Cell Solution Facility 85
Geron Successfully Transplants Pancreatic Islet-Like Clusters 86
StemCells Secures US Patent 86
PerkinElmer Takes Over ViaCell 86
Athersys’ MultiStem® Receives US FDA Nod for Phase I Trial in
BMT Support and AMI 87
BioE Teams Up with Phillips Plastics for Stem Cell Therapeutics 87

11. FOCUS ON SELECT GLOBAL PLAYERS 88
Advanced Cell Technology, Inc. (US) 88
Athersys, Inc. (US) 88
BioE, Inc. (US) 89
Cellartis AB (Sweden) 89
Cryo-Cell International, Inc. (US) 89
Cytori Therapeutics, Inc. (US) 90
ES Cell International (Singapore) 90
Gamida Cell Ltd. (Israel) 91
Genzyme Corporation (US) 91
Geron Corporation (US) 91
International Stem Cell Corporation (US) 92
Mesoblast Ltd. (Australia) 92
Neuralstem, Inc. (US) 93
NeuroGeneration, Inc. (US) 93
Osiris Therapeutics, Inc. (US) 94
StemCells, Inc. (US) 94
ThermoGenesis Corp. (US) 95
ViaCord, LLC (US) 95

12. GLOBAL MARKET PERSPECTIVE 96
Table 4: Global Recent Past, Current & Future Analysis of
Adult Stem Cell Research By Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual
Investment Figures in US$ Million for Years 2006 through 2015
(includes corresponding Graph/Chart) 96

Table 5: World 10-Year Perspective for Adult Stem Cell
Research by Geographic Region - Percentage Breakdown of Annual
Investments for US, Europe and Rest of World Markets for Years
2006, 2010 & 2015 (includes corresponding Graph/Chart) 97

13. THE UNITED STATES 98
A.Market Analysis 98
North America - Spearheading Global Stem Cells Market 98
US - The Market Leader for Stem Cell Research Worldwide 98
Interest in Adult Stem Cell Research Continues 99
Cosmetic Enhancements Ahead of Therapies for Diseases 99
Embryonic Stem Cell Research in the US Held Back by Lack of
Federal Funding 100
Vacillating US Policy on Federal Funding for hESC Research 100
US Revokes Ban On Federal Funding for hESC Research 100
Federal Funding Remains the Key for Further Progress in the
Sector 101
US Court’s Decree to Block Federal Funding for hESC Research
to Affect Biotech Industry 101
Competitive Scenario 102
Table 6: Leading Players in the US Stem Cell Therapeutics
Market (2007): Percentage Breakdown of Value Sales for
ViaCell Inc., Cryo-Cell, Osiris Therapeutics Inc.,
International Stem Cell Corporation, Geron Corp., Cytori
Therapeutics Inc., Athersys Inc., and Others (includes
corresponding Graph/Chart) 102
B.Market Analytics 103
Table 7: US Recent Past, Current & Future Analysis of Adult
Stem Cell Research Market Analyzed with Annual Investment
Figures in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) 103

14. EUROPE 104
A.Market Analysis 104
The UK Policy on hESC Remains In Favor of Developing the
Science 104
UK Adopts Practical Approach In Addressing Moral Issues 104
UK- The First Country to Allow Therapeutic Cloning 104
B.Market Analytics 105
Table 8: European Recent Past, Current & Future Analysis of
Adult Stem Cell Research Market Analyzed with Annual
Investment Figures in US$ Million for Years 2006 through
2015 (includes corresponding Graph/Chart) 105

15. REST OF WORLD 106
A.Market Analysis 106
The Rise of Asia in Stem Cells Research 106
US Ban on Federal Funds for hESC Research Boosts Asian Presence 106
Emergence of China in the Global Stem Cell Research Space 106
The Indian Stem Cell Research Market - An Overview 107
B.Market Analytics 108
Table 9: Rest of World Recent Past, Current & Future
Analysis of Adult Stem Cell Research Market Analyzed with
Annual Investment Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) 108


COMPETITIVE LANDSCAPE

Total Companies Profiled: 90 (including Divisions/Subsidiaries - 97)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 67
Canada 3
Japan 1
Europe 14
France 1
The United Kingdom 7
Spain 1
Rest of Europe 5
Asia-Pacific (Excluding Japan) 9
Latin America 1
Middle-East 2
------------------------------------------